203 related articles for article (PubMed ID: 30822182)
21. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
22. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
[No Abstract] [Full Text] [Related]
23. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results.
Fernandez H; Schmidt T; Powell M; Costa AP; Arriagada P; Thaler C
Eur J Obstet Gynecol Reprod Biol; 2017 Jan; 208():91-96. PubMed ID: 27898340
[TBL] [Abstract][Full Text] [Related]
24. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
Palaia I; Del Negro V; Fracassi A; Schiavi M; Di Donato V; Fischetti M; Muzii L; Benedetti Panici P
Gynecol Endocrinol; 2020 Jul; 36(7):660-661. PubMed ID: 31878806
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology of uterine myomas and clinical practice in Spain: An observational study.
Monleón J; Cañete ML; Caballero V; Del Campo M; Doménech A; Losada MÁ; Calaf J;
Eur J Obstet Gynecol Reprod Biol; 2018 Jul; 226():59-65. PubMed ID: 29852335
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2.
Gemzell-Danielsson K; Heikinheimo O; Zatik J; Poka R; Rechberger T; Hudecek R; Petersdorf K; Ramirez F; Faustmann T; Groettrup-Wolfers E; Seitz C
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():7-14. PubMed ID: 32559602
[TBL] [Abstract][Full Text] [Related]
29. [Ulipristal acetate (Esmya): a selective modulator of progesterone receptors, new treatment of uterine fibromatosis].
Nisolle M; Closon F; Firquet A; Top M; Pintiaux A
Rev Med Liege; 2014 Apr; 69(4):220-5. PubMed ID: 24923103
[TBL] [Abstract][Full Text] [Related]
30. Repeated-intermittent use of ulipristal acetate for the management of uterine fibroids: an Italian pharmacoeconomic evaluation.
Maratea D
Minerva Ginecol; 2016 Feb; 68(1):15-20. PubMed ID: 26990098
[TBL] [Abstract][Full Text] [Related]
31. Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis.
Biscione A; Barra V; Bellone E; Severi FM; Luisi S
Gynecol Endocrinol; 2020 Jan; 36(1):87-92. PubMed ID: 31328597
[TBL] [Abstract][Full Text] [Related]
32. Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.
Lukes AS; Soper D; Harrington A; Sniukiene V; Mo Y; Gillard P; Shulman L
Obstet Gynecol; 2019 May; 133(5):869-878. PubMed ID: 30969201
[TBL] [Abstract][Full Text] [Related]
33. Real-world data of 197 patients treated with ulipristal acetate for uterine fibroids: PREMYA study French population main outcomes.
Fernandez H; Descamps P; Koskas M; Lopès P; Brun JL; Darai E; Agostini A
J Gynecol Obstet Hum Reprod; 2017 Sep; 46(7):559-564. PubMed ID: 28676450
[TBL] [Abstract][Full Text] [Related]
34. Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.
Liu JH; Soper D; Lukes A; Gee P; Kimble T; Kroll R; Mallick M; Chan A; Gillard P; Harrington A; Sniukiene V; Shulman LP
Obstet Gynecol; 2018 Nov; 132(5):1241-1251. PubMed ID: 30303900
[TBL] [Abstract][Full Text] [Related]
35. Unexpected Uterine Leiomyosarcoma During Laparoscopic Hysterectomy Treated 6 Months With Ulipristal Acetate and Contained Power Morcellation.
Istre O
J Minim Invasive Gynecol; 2017 Feb; 24(2):198. PubMed ID: 27539216
[TBL] [Abstract][Full Text] [Related]
36. Three-year outcome of the Halt trial: a prospective analysis of radiofrequency volumetric thermal ablation of myomas.
Berman JM; Guido RS; Garza Leal JG; Pemueller RR; Whaley FS; Chudnoff SG;
J Minim Invasive Gynecol; 2014; 21(5):767-74. PubMed ID: 24613404
[TBL] [Abstract][Full Text] [Related]
37. The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study.
Gunes M; Ozdegirmenci O; Kayikcioglu F; Haberal A; Kaplan M
J Minim Invasive Gynecol; 2008; 15(6):735-8. PubMed ID: 18971138
[TBL] [Abstract][Full Text] [Related]
38. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
39. First Impressions Can Be Deceiving: Surgical Outcomes of Laparoscopic Myomectomy in Patients Pretreated with Ulipristal Acetate.
Frascà C; Arena A; Degli Esposti E; Raimondo D; Del Forno S; Moro E; Zanello M; Mabrouk M; Seracchioli R
J Minim Invasive Gynecol; 2020; 27(3):633-638. PubMed ID: 31419494
[TBL] [Abstract][Full Text] [Related]
40. Ulipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas: Help or Hindrance?
Ferrero S; Vellone VG; Barra F; Scala C
Gynecol Obstet Invest; 2019; 84(4):313-325. PubMed ID: 30554215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
